[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"newborn-sepsis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:newborn-sepsis":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644641",false,"NCT07670624","T6A Biomarker for Detection of Bacterial Infection in Newborn Infants","T6ASepsis","Inclusion Criteria:\n\n* Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant\n* Signed informed consent form\n\nExclusion Criteria:\n\n1. Refusal to participate in study or not providing written informed consent by caregivers\u002Fparents\n2. Antibiotic treatment of any kind.","ALL",{"count":17,"type":18},210,"ESTIMATED","1 Week","OBSERVATIONAL","This study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.",[23,24,25],"Sepsis","Newborn Sepsis","Biomarker Discovery",[27,28,29,30],"t6a","newborn sepsis","infectious disease biomarker","biomarker","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":18},"2026-07-01",{"date":39,"type":18},"2029-01-31",{"name":41,"class":42},"Salzburger Landeskliniken","OTHER",""]